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Radiotelemetric BP monitoring, antihypertensives and glomerulopro-
tection in remnant kidney model. The mechanisms by which antihyper-
tensives exert a glomeruloprotective effect in the remnant kidney model
remain controversial. Based on periodic tail-cuff BP measurements, the
variable glomeruloprotective efficacy of antihypertensive agents has been
ascribed to mechanisms other than or in addition to their ability to lower
BP. To more precisely define the relationship between BP control and
glomeruloprotection, systolic BP was continuously monitored radiotele-
metrically at 10-minute intervals for —65 days in rats after —5/6 renal
ablation. Rats with remnant kidneys received either no therapy or one of
three antihypertensive regimens in their drinking water after the first
week: enalapril, a triple therapy regimen (reserpine, hydralazine, hydro-
chlorothiazide); or a high dose triple therapy regimen. Although all
antihypertensive regimens significantly lowered BP, considerable inter-
animal variability was observed. Additionally, marked lability of BP was
present in both untreated and treated rats. Glomerular injury in individual
animals (N = 34) was very strongly correlated with their overall averaged
systolic BP during the final eight weeks (r = 0.91) and with the frequency
of systolic BP readings >150 mm Hg (r = 0.89). These data do not provide
evidence of a therapeutic advantage for any of the regimens independent
of their antihypertensive effects but indicate that the glomeruloprotective
efficacy of these antihypertensive regimens is directly proportional to their
antihypertensive efficiency.
The phenomenon of the progressive nature of human renal
disease has been extensively investigated using the rat remnant
kidney (RK) model. This model produced by right nephrectomy
and segmental infarction of two-thirds of the left kidney is
characterized by adaptive increases in size and function of the
remnant glomeruli [1—5]. With time these RK rats develop
proteinuria, hypertension and progressive glomerulosclerosis, the
pathogenesis of which remains controversial. Although hyperten-
sive mechanisms have been postulated to play a major pathoge-
netic role [6—111, antihypertensive therapies have not been uni-
formly glomeruloprotective despite adequate and equivalent BP
control as judged by periodic tail-cuff BP measurements [12—17].
This has led to the concept that the glomeruloprotective efficacy
of antihypertensive agents depends on mechanisms other than or
in addition to their ability to lower systemic blood pressure. It has
been suggested that antihypertensives differ in their ability to
lower intraglomerular pressure (PGC) despite comparable reduc-
tions in systemic blood pressure and that antihypertensive regi-
Received for publication September 28, 1993
and in revised form April 6, 1994
Accepted for publication May 10, 1994
© 1994 by the International Society of Nephrology
mens that do not lower P0 are not glomeruloprotective [13].
Others have suggested that glomeruloprotection with antihyper-
tensive agents is independent of Gc but depends on their ability
to inhibit the glomerular hypertrophic response after renal mass
reduction [15]. Our recent studies using the radiotelemetric
technique of continuous blood pressure monitoring [18] in this
model have demonstrated marked spontaneous lability of blood
pressures and have suggested that the tail-cuff method may not be
adequate to assess completely the blood pressure profiles in these
animals [19]. The present studies were undertaken to examine
more critically the relationship of blood pressure control with
different antihypertensive regimens to glomerular injury in indi-
vidual RK rats utilizing this radiotelemetric technique.
Methods
The studies were performed on male Sprague-Dawley rats
(body wt 200 to 300 g) who were fed a standard 22% protein diet
and synchronized to a 12:12 hour light (6:00 to 18:00 hours) and
dark (18:00 to 6:00 hours) cycle. After baseline tail-cuff systolic
blood pressure measurements (Apollo 179 Analyzer, IITC/Life
Science Instruments, California, USA) in unanesthetized re-
strained rats the animals were anesthetized with sodium pento-
barbital (45 mg/kg i.p.) and subjected to —5/6 renal ablation (right
nephrectomy and ligation of all but one posterior extrarenal
branch of the left renal artery) [7, 11]. At the time of surgery, rats
were prepared for telemetric monitoring of blood pressure (Data
Sciences, Inc., Minnesota, USA) [18, 19]. Each rat had a blood
pressure sensor (model TA1 1PA-C40) inserted intraperitoneally.
The sensor's catheter was inserted into the aorta below the level
of the renal arteries, and the radio-frequency transmitter was fixed
to the peritoneum. The rats were housed individually in plastic
cages which were placed on top of the receiver. The signals from
the pressure sensor were converted, temperature compensated
and sent via the radio-frequency transmitter to the telemetry
receiver. The receiver was connected to a BCM-100 consolidation
matrix which transmitted the information to the Dataquest IV
acquisition system. Systolic blood pressure in each animal was
continuously recorded at 10-minute intervals for the duration
(—65 days) of the study. All rats received food and water ad
libitum throughout the study.
In most rats, tail vein blood samples were obtained at three days
for measurement of serum creatinine (Sr) as an index of the
degree of renal mass reduction. At —7 days, randomly selected
rats with —5/6 renal ablation received either no treatment (NT) or
one of the following regimens in drinking water: enalapril (E) 50
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mg/liter; triple therapy (TT) with reserpine 5 mg/liter, hydralazine
80 mg/liter and hydrochlorothiazide 25 mg/liter [14]; or high dose
triple therapy (HDTF) with reserpine 10 mg/liter, hydralazine 200
mg/liter, and hydrochlorothiazide 50 mg/liter [15]. The treatment
regimens were continued through the remainder of the animals'
course. During the course of the study, one HDTT and two NT
animals died. The data for these animals were not included in this
analysis. The data for an additional rat treated with the HD'lT
regimen were excluded due to the discovery of obstructive hydro-
nephrosis at the time of the clearance studies. The numbers of
animals for each group available for final analysis were: NT (N =
8); E (N = 8); iT (N = 12), and HDTT (N = 6). At the end of
the study (—65 days), 24 hour urine collections for protein
excretion were obtained. The rats were then anesthetized with
intravenous sodium pentobarbital (40 mg/kg); a tracheostomy was
performed using polyethylene (PE-200) tubing and they were
surgically prepared for clearance studies as previously described
[7, 11]. A carotid artery was cannulated with PE-50 tubing and
connected to a Gould Windograf (Model 40-8474) for continuous
recording of mean systemic pressure. A femoral vein was cannu-
lated with polyethylene tubing (PE-50) and a priming dose of
inulin in 150 mM NaC1 was administered, followed by a continuous
maintenance infusion of 150 mM NaCI containing inulin 0,055
ml/min to maintain the plasma concentration at —50 mg/dl and
for replacement of surgical and ongoing fluid losses. The left
ureter was then cannulated with polyethylene tubing for collection
of urine samples. A 1.0 mm Transonic R series flow probe was
placed around the left renal artery for measurement of renal
blood flow (RBF) by the Transonic flowmeter (Transonic Sys-
tems, New York, USA), as previously described [20]. At the
conclusion of the surgery, a 150 mM NaCl bolus equal to 1% of
body weight was administered. Two 20-minute clearances of
inulin were obtained. Blood samples were obtained at the mid-
point of each urine collection.
At the conclusion of these studies the rats were sacrificed and
the kidneys were harvested for morphological studies. A trans-
verse section of the kidney through the papilla was fixed in 10%
neutral buffered formalin and embedded in paraffin. Sections
were cut at 4 tm thickness and stained with hematoxylin and
eosin (H&E) and Periodic acid-Schiff (PAS) stains. Sections were
evaluated systematically in each kidney for glomerular injury
(segmental sclerosis and/or necrosis) in a blinded fashion by
standard morphologic methods. At least 100 glomeruli in each
animal were evaluated and the severity of glomerular injury was
expressed as the percent of glomeruli exhibiting such injury.
Additionally, semiquantitative glomerular injury scores for indi-
vidual kidneys were also derived based on the percentage of
glomerular surface area involved [21]. A score of 1 was given for
0 to 25%; 2 for 25 to 50%; 3 for 50 to 75%; and 4 for 75 to 100%
glomerular surface area involvement with a maximum obtainable
score of 400.
Analyses, calculations, and statistics
Urinary protein was measured by the quantitative sulfosalicyclic
acid method with human serum albumin serving as standard.
Serum creatinine was measured using a Beckman creatinine
analyzer [7, 11]. Inulin in urine and plasma filtrates was deter-
mined spectrophotometrically by the diphenylamine method as
previously described [7, 11]. Glomerular filtration rate was calcu-
lated using standard formulae.
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Fig. 1. The course of systolic blood pressure after —5/6 renal ablation in the
four groups of rats. BP was radiotelemetrically recorded continuously at
10-minute intervals for the duration of the study. The 24 hour averages of
BP at 5 day intervals are shown. After the first 7 days, the rats received
either no treatment (D, N 8) or one of the following regimens in
drinking water: enalapril (,N = 8) 50 mg/liter; triple therapy (V, N
12) with reserpine 5 mg/liter hydralazine 80 mg/liter and hydrochlorothi-
azide 25 mg/liter; or high dose triple therapy (A, N = 6) with reserpine 10
mg/liter, hydralazine 200 mg/liter and hydrochlorothiazide 50 mg/liter.
The results are expressed as mean SE. Statistical analysis was
performed using analysis of variance (ANOVA) followed by
Student-Newman-Keuls test. Differences within a group were
analyzed by the Student's paired t-test. A P value of <0.05 was
considered statistically significant.
Results
Figure 1 illustrates the course of BP after ——5/6 renal ablation
and the effects of the different antihypertensive regimens over
—65 days of the study. The 24 hour averages of systolic BP at five
day intervals are plotted for convenience of illustration. All three
treatment regimens significantly reduced BP when compared to
the untreated group, but HDTT and E were more successful than
Ti' in maintaining BP control. This is supported by the data in
Table 1 which present the overall averages of systolic blood
pressures for the first 10 days and the final —eight weeks in each
of the study groups. The systolic blood pressure averages were not
significantly different between the untreated and treated groups
during the first 10 days except for the HDTT rats which were
significantly higher (P < 0.05) than the other groups for unclear
reasons. A significant antihypertensive effect was observed with all
three regimens as indicated by the lower overall SBP averages
during the final —eight weeks as compared to their systolic BP
during the first 10 days (P < 0.001), paired t-test. In contrast, the
average systolic BP during the final eight weeks in the untreated
group was not significantly different from that during the first 10
days. Similarly, when the overall BP averages of the groups during
the final —eight weeks are compared the E (119 5.3 mm Hg),
HDTT (127 6.7 mm Hg) and TT (133 7.5 mm Hg) groups
were significantly lower (P < 0.05) compared to the untreated NT
(158 9 mm Hg) group. Figure 2 A through D illustrates
representative 12 hour recordings of systolic blood pressure at
10-minute intervals in a rat from each of the four experimental
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Table 1. Blood pressure averages (mm Hg)
Final —8 weeks
groups. These figures graphically display the spontaneous variabil-
ity and fluctuations in systolic blood pressure in this model. The
fluctuations in BP observed in the untreated control group
persisted in the treated animals. This is also indicated by the lack
of any significant differences in the standard deviations of the
overall BP averages in the four groups (Table 1). However, a
differential effect of the antihypertensive regimens on the diurnal
rhythm was noted. The nighttime pressures were modestly but
significantly higher in the untreated (NT) rats. This circadian
rhythm was preserved in the E group, but was lost in the Ti' and
HDTT groups.
Although Sr at three days was not obtained in all animals due
to technical difficulties, no significant differences were present
between the groups based on the measurements that were ob-
tained in a majority of animals in each group suggesting compa-
rable renal mass reduction (0.9 0.07 mg/dl in 6/8 NT; 0.85
0.05 mg/dl in 5/8 E; 0.89 0.05 mg/dl in 9/12 Ti'; and 0.94 0.07
mg/dl in 5/6 HDTT). Table 2 presents the data for the final body
weight, 24 hour urine protein excretion, renal blood flow (RBF),
and GFR in the four groups. There were no significant differences
between body weights, RBF (mI/mm/kg), and GFR (mi/mm/kg)
between the four groups. There was a trend to reduction in
urinary protein excretion (mg/day) with blood pressure control
but this reached statistical significance only in the E group (22
7.8 mg/24 hr) as compared to the untreated rats (66 10.6 mg/24
hr; P < 0.05). Data for glomerular injury in the four groups are
also presented in Table 2. The glomerular injury is expressed both
as percent of glomeruli exhibiting injury as well as the calculated
glomerular injury score.
Figure 3 A through D illustrates the range of glomerular
pathology observed in the present study and that was used to
calculate the glomerular injury scores in individual animals.
Although there was a trend toward a decrease in the total percent
of glomeruli exhibiting injury and in the glomerular injury score,
paralleling the decrease in BP (glomerular injury was lowest in the
E group and highest in the NT group, Table 2), the differences did
not reach statistical significance in group comparisons due to the
scatter within the groups (ANOVA). However, when glomerular
injury was correlated with the parameters of telemetrically mon-
itored systolic blood pressures in individual RK rats, there was an
First 10 days Overall Std Dev
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Rats with remnant kidneys underwent continuous radiotelemetric monitoring of systolic BP at 10-minute intervals for 65 days. After the first 7 days,
rats received either no treatment (NT) or one of three antihypertensive regimens in drinking water: enalapril (E), triple therapy (TT) regimen
(reserpine, hydralazine and hydrochiorothiazide), or high dose triple therapy (HDTT) regimen. See text for dosages.
a P < 0.05 compared to NT, ANOVA; h <0.0005 compared to first 10 days; paired t-test: Cp <0.001 compared to daytime, paired t-test. Day time
6 am. to 6 p.m.: nighttime 6 p.m. to 6 am.
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Fig. 2. illustrations of systolic blood pressure
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___________________________ from each of the four groups: (a) untreated (NT);
(b) enalapril (E); (c) triple therapy (TT) regimen
(reseipine, hydralazine, hydrochiorothiazide); (d)
high dose triple therapy (HDTT) regimen. See text
for details of dosage regimens.
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Fig. 3. An illustration of the range of glomerular pathology used to calculate the glomerular injuFy in the present study. (A) Less than 25% of glomerular
tuft involvement with a segmental increase in mesangial matrix and collapse of the adjacent glomerular capillaries. There is also a small adhesion with
Bowman's capsule (Score 1) H&E x 625. (B) Between 25 to 50% of glomerular tuft involvement with segmental collapse of glomerular capillaries,
increase in mesangial matrix and broad adhesions with Bowman's capsule (Score 2) H&E >< 625.
Fig. 3. Continued. (C) Fifty to 75% of tuft involvement with segmental sclerosis and hyalinosis (Score 3). PAS)< 625. (D) Grade IV: greater than 75%
of the glomerular tuft is obliterated by sclerosis. There are also broad adhesions with Bowman's capsule (Score 4). PAS x 625.
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Table 2. Final functional and morphologic data
Body wt
g
Proteinuria
mg/24 hr
RBF
mi/mm/kg
GFR
mi/mm/kg
Glomerular iniur
% Score
NT (N = 8) 508 18 66.4 10.6 18.9 1.9 2.0 0.3 47.8 9.6 99.3 36.9
E (N = 8) 467 31 22.6 4.8 23.1 1.6 2.9 0.4 18.0 6.1 27.0 9.2
YF (N = 12) 491 24 57.6 10.5 22.2 1.6 2.3 0.2 36.1 6.6 70.6 28.9
HDTF (N = 6) 415 30 37.5 12.0 21.3 1.7 2.4 0.5 27.3 10.6 56.8 35.4
Rats with remnant kidneys underwent continuous radiotelemetric monitoring of systolic BP at 10-minute intervals for —65 days. After the first 7 days,
rats received either no treatment (NT) or one of three antihypertensive regimens in drinking water: enalapril (E), triple therapy (TI') regimen
(reserpine, hydralazine and hydrochlorothiazide), or high dose triple therapy (HDTF) regimen. See text for dosages.P < 0.05 compared to NT, ANOVA
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(Final 8 weeks)
Fig. 4. Con-elation of percentage of glomendi with injuly (focal and segmen-
tal sclerosis and/or necrosis) in individual rats from all four groups with their
overall averaged systolic BP for the final —8 weeks. Systolic BP was
telemetrically recorded every 10 minutes for the duration of the study.
After the 7th day, the rats had received either no treatment (; N = 8) or
one of these regimens in drinking water: enalapril (U, N = 8); triple
therapy (A, N = 12); or high dose triple therapy (A, N = 6). See text for
details of dosage regimens. r = 0.91.
Overall averaged systolic BP, mm Hg
(Final 8 weeks)
Fig. 5. Con-elation of the glomerular injury score derived from the percent
area of the giomendus exhibiting injury by the method of Raij et a! [20] in
individual rats with their overall averaged systolic BPfor the final —8 weeks.
Systolic BP was telemetrically recorded every 10 minutes for the duration
of the study. After the 7th day, the rats had received either no treatment
(0, N 8) or one of these regimens in drinking water: enalapril (U, N =
8); triple therapy (A, N = 12); or high dose triple therapy (A, N = 6). See
text for details of dosage regimens. r = 0.84.
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excellent correlation of percent glomerular injury and overall
mean systolic blood pressure during the final —eight weeks in
individual rats (r = 0.91, P < 0.0001; Fig. 4). Similar excellent
correlations between these two parameters were observed within
each group: NT (N = 8),r = 0.96, P < 0.0002; E (N 8), r = 0.94,
P < 0.0005; TF (N = 12), r = 0.93, P < 0.0001; and HDTT (N =
6), r = 0.88, P < 0.02. The slopes of the relationship between
overall averaged systolic BP for the final eight weeks and glomer-
ular injury in the four groups were not significantly different from
each other, NT, 1.03 0.13; E, 1.09 0,16; TT, 0.82 0.10 and
HDTT, 1.41 0.37, or from the slope for all animals combined
(0.88 0.07, Fig. 4). When glomerular injury was expressed in the
form of calculated glomerular injury scores based on the percent
glomerular surface area exhibiting injury, a similar strong corre-
lation was observed with the overall averaged systolic blood
pressure for the final eight weeks (r =0.84,P < 0.0001; Fig. 5). A
similar excellent correlation was also observed between percent
glomerular injury and frequency with which a systolic blood
pressure reading of >150 mm Hg was obtained as a percentage of
the total readings in individual rats after the first 10 days (r =0.89,
P < 0.0001; Fig. 6). The correlations of overall averaged systolic
BP with other non-histologic parameters at the end of the study
showed a weaker but significant correlation with proteinuria (r =
0.51, P < 0.005; Fig. 7) and GFR (r = 0.55, P < 0.001). The
correlation with RBF was not statistically significant (r =0.33,P > 0.05). Similarly, while both proteinuria and GFR were
significantly correlated with glomerular injury, the correlations in
individual animals were not very strong: proteinuria (r = 0.53,P <
0.002); GFR (r = 0.64, P < 0.0001). In contrast, no significant
correlation was observed between RBF and glomerular injury in
individual animals (r = 0.33, P > 0.05).
Discussion
The spontaneous variability of blood pressure in the non-
anesthetized state has been documented in several species includ-
ing rats and humans [18, 22—25]. Using the radiotelemetric
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Fig. 6. Correlation of percentage of glomeruli with injury in individual rats
from all four groups with the frequency with which a systolic BP reading of
>150mm Hg was recorded as a percentage of total readings for the final —8
weeks. Systolic BP was telemetrically recorded every 10 minutes for the
duration of the study. After the 7th day, the rats had received either no
treatment (E, N = 8) or one of these regimens in drinking water: enalapril
(U,N = 8); triple therapy (A, N = 12); or high dose triple therapy (A, N
= 6). See text for details of dosage regimens. r 0.89.
technique of continuous HP monitoring, we have recently docu-
mented a marked increase in the spontaneous lability of blood
pressure after —5/6 renal ablation as compared to control sham
operated rats [19]. The present studies demonstrate that this
spontaneous lability persists during antihypertensive therapy and
may have significant implications for BP measurements in studies
of this model. The present studies also show that antihypertensive
regimens may have divergent effects on circadian rhythms. The
normal diurnal variation in BP observed in the untreated group
was maintained in rats treated with E. In contrast both the HDTT
or TI' regimens abolished this circadian rhythm. The specific
agent(s) and mechanism(s) responsible for this loss of diurnal
variation remain to be determined.
An excellent correlation was observed between glomerular
injury and the average of —-8000 fluctuating BP readings in
individual untreated and treated rats after —5/6 renal ablation in
the present study. The results are consistent with a predominant
role for hypertensive mechanisms in the pathogenesis of glomer-
ular injury. The glomeruloprotection which was achieved paral-
leled the antihypertensive effects in these rats, within and between
groups. Although the present study was not designed to establish
the relative merits of these therapeutic regimens in this model by
group comparisons, evidence of glomerulprotective ability, inde-
pendent of their antihypertensive effects, was not observed for any
of the therapeutic regimens used in the present study. This is
indicated by the lack of significant differences between the slopes
of the relationship between blood pressure and glomerular injury
in the four groups. However, in the dosages used, the converting
enzyme inhibitor, enalapril, was the most consistently effective.
The HD1T regimen was almost as effective and the TI' regimen
was the least effective. Our data suggest that such differences
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Fig. 7. Correlation ofproteinuria in individual rats from all four groups with
the overall averaged systolic BP for the final 8 weeks. Systolic HP was
telemetrically recorded every 10 minutes for the duration of the study.
After the 7th day, the rats had received either no treatment (D, N = 8) or
one of these regimens in drinking water: enalapril (U, N = 8); triple
therapy (A, N = 12); or high dose triple therapy (A, N = 6). See text for
details of dosage regimens. r = 0.51.
between the groups are, at least for the most part, a function of
the effectiveness of these regimens in controlling systemic hyper-
tension in individual animals and that the superior glomerulopro-
tective ability of enalapril is largely a consequence of its superior
consistency as an antihypertensive in this model. However, addi-
tional beneficial effects of converting enzyme inhibitors cannot
definitively be excluded.
The results of the present study indicating that the glomerulo-
protective efficacy of these therapeutic regimens is directly pro-
portional to their antihypertensive efficiency, are at seeming
variance with the conclusions of most of the previous studies of
these antihypertensive agents in this model [12, 13—15]. Anderson,
Rennke, and Brenner compared triple therapy to enalapril in
dosage regimens identical to those used in the present study and
found that both regimens resulted in similar BP control as
determined by tail-cuff BP measurements [13]. Glomeruloprotec-
tion was however, only observed in the enalapril group, suggesting
that control of systemic HP alone, as obtained with the triple
therapy (fl) regimen, was not sufficient to prevent glomerulo-
sclerosis in this model. Kakinuma et al also documented a similar
ineffectiveness of the TI' regimen in halting the progression of
glomerulosclerosis in this model as compared to angiotensin
converting enzyme inhibitors despite the attainment of equivalent
systemic blood pressure using the tail-cuff method [14]. Similarly,
Purkerson, Hoffsten, and Klahr concluded that only partial pro-
tection could be obtained in this model with afl regimen despite
the achievement of adequate and satisfactory control of hyperten-
sion [12]. By contrast, Yoshida et al were able to achieve a degree
of glomeruloprotection comparable to enalapril using a higher
dose triple therapy regimen identical to the HDTI' in the present
study [15]. The tail-cuff pressures achieved with this regimen by
Yoshida et al were comparable to enalapril and no different than
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that reported in other studies with the standard TF regimen.
Although these studies differed in the postulated mechanisms
of protection, they reached the similar conclusion that glomeru-
loprotective effects of these therapeutic regimens were, at least in
part, independent of their effects on the systemic BP. The
interpretations in these studies are greatly dependent on the
adequacy of the periodic tail-cuff BP measurements to reflect the
ambient blood pressure profiles in both treated and untreated
animals. The significant spontaneous lability of BP observed by
radiotelemetry in both treated and untreated rats in the present
study suggests that the tail-cuff method may not be adequate to
fully assess ambient blood pressures in this model. Moreover,
considerable variability in the BP response to each of the antihy-
pertensive regimens was noted in individual animals in the present
study. It is possible that similar undetected variability in BP
responses may account for the variable and often conflicting
results that have been obtained with similar therapeutic regimens
by different investigators in this model [12—17].
The mechanism of protection, when protection has been
achieved in these studies, is also the subject of significant dispute
[13, 15, 16, 26]. Anderson, Rennke, and Brenner attributed the
glomeruloprotective efficacy of enalapril to its ability to lower P0
and the failure of the IT regimen to glomeruloprotect to its
inability to similarly lower Gc [13]. This was ascribed to the
preferential efferent arteriolar dilation achieved by enalapril.
Yoshida et al also found that enalapril, but not HDTT, lowered
Gc [15]. However, in contrast to the results of Anderson,
Rennke, and Brenner, glomeruloprotection was seen in both
groups. Therefore, Yoshida et al concluded that a decrease in P0,
was not necessary for protection and that glomeruloprotection
was mediated by the ability of both enalapril and HDTF to reduce
the hypertrophic response after —5/6 renal mass reduction. These
seemingly irreconcilable observations about the pathogenetic
significance of P0 in this model are both dependent on the
assumption that isolated measurements of Gc obtained under
anesthesia are an accurate and adequate index of ambient gb-
merular capillary pressures. However, the limitations that have
been demonstrated for periodic tail-cuff blood pressure measure-
ments in the present study are probably also true for P0
measurements. The interpretations of Gcmeasurements in these
and other studies in the RK model have been made with the
assumption that glomerular capillary pressures remain relatively
stable with little variability [27—29]. For this inference to be valid,
it is necessary that either the systemic BP not exhibit significant
lability or that the autoregulatory mechanisms that normally
prevent the transmissions of fluctuations in systemic pressures to
the glomerular capillaries be intact [30]. By contrast, the RK
model is characterized by both marked lability of BP [18, present
study as well as impaired autoregulation, as has been demon-
strated by us and others [7, 11, 31, 32]. Micropuncture studies
have indeed demonstrated parallel changes in P0ç in response to
changes in arterial pressures, produced either mechanically [31,
32] or pharmacologically [33, 34]. Therefore, it is likely that
pressures in the glomerular capillaries exhibit qualitatively similar
lability in parallel with the systemic pressures. Episodes of acutely
increased systemic pressures, even if of limited duration, would be
expected to be communicated to the glomerular capillaries.
Therefore, the transmission of hypertension to glomerular capil-
laries in this model is likely to be a much more dynamic process
then can be appreciated by isolated measurements of steady-state
systemic and/or glomerular pressures. The exceedingly close
correlations of glomerular injury in the present study with overall
averaged BP over a 65 day period and with the frequency of BP
measurements >150 mm Hg, regardless of treatment modality,
provide strong support for such an interpretation. Given the
potential lability of glomerular capillary pressures, the lack of
consistent correlations of isolated P0. measurements with glomer-
ular injury is not entirely unexpected [15, 28, 29]. Alternatively, it
is possible that both systemic hypertension and glomerular injury
are separate but parallel consequences of some other underlying
pathogenetic mechanism or that they are very closely linked
together, but by some mechanism other than that of glomerular
transmission. However, there is no evidence at present to support
such postulates.
Regardless of the precise mechanisms of glomerular injury, or
the mechanism by which antihypertensive agents are protective,
the present studies demonstrate that the degree of glomerulopro-
tection achieved is very closely correlated with the degree of
reduction in systemic BP, provided the systemic pressures are
precisely measured. Additionally, these data indicate that such a
reduction in hypertension may be necessary for glomeruloprotec-
tion regardless of the therapeutic regimen that is used. The
persistence of the spontaneous lability of BP despite antihyper-
tensive treatment and the documentation of similar lability in
hypertensive humans [24, 25] suggest a need for more rigorous BP
monitoring in evaluating antihypertensive regimens in patients
with renal disease. This may be particularly important in the
management of patients in whom an enhanced glomerular trans-
mission of systemic hypertension is thought to occur such as in
patients with renal insufficiency and/or diabetes [3, 8, 35, 36]. It is
of interest that recent studies utilizing ambulatory BP in humans
have also suggested that end organ damage in hypertension is
related to 24 hour BP variations [25, 37]. Finally, these data
emphasize the limitations of occasional measurements of systemic
and/or glomerular pressures in the assessment of the role of
hypertensive mechanisms in the pathogenesis of glomerular injury
after renal mass reduction.
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